These data demonstrate the effective and safe OPAT use of telavancin, providing an alternative for successful treatment of patients with osteomyelitis” Schroeder et al (2017).
Abstract:
Telavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens including Staphylococcus aureus, the most frequent cause of osteomyelitis. Treatment is often challenging due to needs for surgical intervention along with prolonged administration of intravenous antimicrobials, frequently in an outpatient setting.
[ctt link=”a280D” template=”1″]ReTweet if useful… How effective is OPAT treatment of osteomyelitis with telavancin https://ctt.ec/a280D+ @ivteam #ivteam[/ctt]
This was a retrospective analysis of the efficacy and safety of telavancin for treatment of osteomyelitis provided as outpatient parenteral antimicrobial therapy (OPAT) in physician office infusion centres. Medical records of 60 patients receiving telavancin for osteomyelitis in 22 physician office infusion centres from 2010-2011 and 2013-2015 were reviewed. Of these, 60% were treated without hospitalisation, 37% had orthopaedic hardware and 56% had concurrent infections. Staphylococcus aureus was the most common pathogen (78%), primarily methicillin-resistant. The median duration of telavancin treatment in the outpatient setting was 21 days (range 3-105 days). Telavancin was used as first-line therapy in 32% of cases, following prior antibiotic failure in 47% and due to intolerance to previous agents in 22%, predominantly daptomycin or vancomycin. The telavancin dose was 10 mg/kg/day, adjusted for renal function in 25% of patients. The majority of patients self-administered telavancin at home via an elastomeric infusion pump. Overall clinical success was 73%. No significant differences in outcomes were observed with the presence of hardware, concurrent infection, concomitant therapies or type of osteomyelitis. Telavancin-associated adverse events occurred in 57%, with discontinuation in three patients (5%). These data demonstrate the effective and safe OPAT use of telavancin, providing an alternative for successful treatment of patients with osteomyelitis.
Reference:
Schroeder, C.P., Van Anglen, L.J., Dretler, R.H., Adams, J.S., Prokesch, R.C., Luu, Q. and Krinsky, A.H. (2017) Outpatient treatment of osteomyelitis with telavancin. International Journal of Antimicrobial Agents. April 26th. [Epub ahead of print].
doi: 10.1016/j.ijantimicag.2017.01.034.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]